Latest California Healthline Stories
In Debate, Pence and Harris Offer Conflicting Views of Nation’s Reality
During this, the first and only vice presidential debate of the 2020 election season, the two candidates clashed over the coronavirus and other health care issues, as well as a range of other topics.
Distrusting Trump, States Plan to Vet COVID Vaccines Themselves. Bad Idea, Say Experts.
California and at least five other states have said they may independently vet any vaccines. Experts warn that could needlessly confuse the public.
5 Things to Know About a COVID Vaccine: It Won’t Be a ‘Magic Wand’
Approval of a vaccine will be an important step in defeating COVID-19. But it won’t immediately end the pandemic.
5 cosas que debes saber sobre la vacuna para COVID. Primero: no será una “bala mágica”
Hay docenas de vacunas candidatas que se están probando, y 11 de ellas están en la etapa final de investigación, cuatro en los Estados Unidos.
These Secret Safety Panels Will Pick the COVID Vaccine Winners
Data and safety monitoring boards work under a cloak of secrecy meant to prevent undue influence by stakeholders, such as companies or the government. In the Trump era, some worry the anonymity could actually invite it.
Signs of an ‘October Vaccine Surprise’ Alarm Career Scientists
President Donald Trump has the legal power to authorize a COVID vaccine over the objections of the Food and Drug Administration and vaccine manufacturers. Such a move could further erode public trust in a vaccine and foist an unsafe shot on Americans.
Señales de una “vacuna sorpresa en octubre” alarma a científicos de carrera
El presidente Donald Trump, que parece decidido a anunciar una vacuna para COVID-19 antes de las elecciones, podría autorizarla legalmente a pesar de las objeciones.
KHN and California Healthline staff made the rounds on national and local media this week to discuss their stories. Here’s a collection of their appearances.
COVID Vaccine Trials Move at Warp Speed, But Recruiting Black Volunteers Takes Time
The National Institutes of Health has suggested minorities should be overrepresented in COVID-19 vaccine trials — perhaps at rates that are double their percentage of the U.S. population. But efforts to recruit patients from racial minority groups are just beginning, while some trials have already advanced to phase 3.
NIH ‘Very Concerned’ About Serious Side Effect in Coronavirus Vaccine Trial
The AstraZeneca trial is on hold in the U.S. as scientists try to unravel whether a rare neurological condition is linked to the vaccine. But regulators are frustrated by a lack of information from the drugmaker.